When clinics source compounded GLP-1 medications, they often encounter two distinct formulation types: lyophilized (freeze-dried) preparations and liquid (aqueous solution) preparations. Both can deliver the same active ingredient, but they differ significantly in stability, storage requirements, beyond-use dates, and how they are prepared for administration.

Choosing the right formulation for your clinic is not just a preference question — it affects your compliance posture, your staff workflow, and your patients' experience. This post gives you a clear, side-by-side comparison so you can make an informed decision.

Lyophilization, also called freeze-drying, is a process that removes water from a preparation by first freezing it and then reducing the surrounding pressure to allow the frozen water to sublimate (transition directly from solid to gas). The result is a dry powder or cake that retains the active ingredient in a stable, concentrated form.

To use a lyophilized preparation, it must be reconstituted — typically by adding bacteriostatic water for injection (BWFI) or sterile water for injection (SWFI) to the vial and allowing the powder to dissolve.

Lyophilized preparations are common in pharmaceutical manufacturing for compounds that are unstable in aqueous solution. Many peptide-based drugs, including GLP-1 receptor agonists, are candidates for lyophilization because peptides can degrade in water over time.

A liquid GLP-1 preparation is a ready-to-use aqueous solution. The active ingredient is already dissolved in a suitable solvent system (typically water with appropriate pH adjusters, stabilizers, and sometimes a preservative). No reconstitution is required — the preparation is drawn directly from the vial and administered.

Liquid preparations are more convenient from a workflow standpoint but require more careful formulation design to maintain stability in solution over the intended BUD period.

The fundamental difference between lyophilized and liquid GLP-1 preparations comes down to stability.

Peptides like semaglutide and tirzepatide are susceptible to several degradation pathways in aqueous solution:

• Hydrolysis: Water molecules cleave peptide bonds, breaking the molecule apart
• Oxidation: Reactive oxygen species attack susceptible amino acid residues
• Aggregation: Peptide molecules clump together, forming particles that reduce potency and can cause immunogenic reactions
• Deamidation: Asparagine and glutamine residues lose an amide group, altering the peptide structure

Lyophilization removes the water that drives most of these degradation pathways. A properly lyophilized preparation can have a significantly longer shelf life than the equivalent liquid preparation.

However, once a lyophilized preparation is reconstituted, it becomes an aqueous solution and is subject to the same degradation pathways as a liquid preparation. The BUD after reconstitution is typically much shorter than the BUD of the lyophilized powder.

This is where the practical difference becomes most apparent for clinics:

Lyophilized preparations (before reconstitution):

• Typically assigned longer BUDs — potentially 30–90 days or more under refrigeration, depending on the pharmacy's stability data
• Some lyophilized preparations may be stable at room temperature for limited periods, which can simplify shipping

Lyophilized preparations (after reconstitution):

• BUD drops significantly after reconstitution — often 14–28 days refrigerated, depending on the formulation and whether a preservative is used
• Must be stored refrigerated after reconstitution
• Must be used within the post-reconstitution BUD, not the pre-reconstitution BUD

Liquid preparations:

• BUD depends on the formulation and the pharmacy's stability data
• Under USP <797> Category 2 defaults, up to 45 days refrigerated for aqueous preparations
• With extended stability testing, potentially longer
• No reconstitution step — BUD applies from the time of compounding

Lyophilized:

• Pre-reconstitution: Often refrigerated (2–8°C), though some formulations may tolerate room temperature for limited periods
• Post-reconstitution: Must be refrigerated (2–8°C)
• More forgiving of brief temperature excursions before reconstitution than liquid preparations
• Sensitive to moisture — must be kept in sealed vials

Liquid:

• Must be refrigerated (2–8°C) throughout the supply chain and at the clinic
• More sensitive to temperature excursions than lyophilized preparations
• Freeze-thaw cycles can damage the preparation and should be avoided

The reconstitution step required for lyophilized preparations adds complexity to your clinic workflow. Staff must:

1. Verify the lyophilized vial is within its pre-reconstitution BUD
2. Use the correct diluent (BWFI or SWFI) in the correct volume
3. Add the diluent using aseptic technique
4. Allow the powder to dissolve completely (do not shake vigorously — swirl gently)
5. Inspect the reconstituted solution for particulates and clarity
6. Label the vial with the reconstitution date and post-reconstitution BUD
7. Store the reconstituted vial refrigerated

This process requires trained staff and introduces additional steps where errors can occur. Clinics with high patient volume may find the reconstitution workflow burdensome.

Liquid preparations eliminate the reconstitution step entirely, simplifying workflow and reducing the potential for reconstitution errors.

Lyophilized preparations are generally more robust during shipping than liquid preparations:

• Less sensitive to brief temperature excursions during transit
• Some formulations can be shipped at ambient temperature, reducing cold-chain shipping costs
• Lower risk of degradation if a cold-chain failure occurs during shipping

Liquid preparations require strict cold-chain shipping throughout:

• Must be maintained at 2–8°C from the pharmacy to the clinic
• Temperature excursions during shipping can compromise the preparation and invalidate the BUD
• Require insulated packaging with ice packs or dry ice, depending on transit time

The right choice depends on your clinic's specific situation:

Consider lyophilized if:

• You have lower patient volume and need longer pre-reconstitution BUDs to avoid waste
• Your shipping conditions are variable or you are in a warm climate
• You have trained staff comfortable with reconstitution procedures
• You want the flexibility of a preparation that is more stable before use

Consider liquid if:

• You have high patient volume and can use preparations quickly
• You want to minimize staff training and workflow complexity
• You have reliable cold-chain shipping from your pharmacy partner
• You prefer a ready-to-use format with no reconstitution step

Many clinics use both formats depending on the specific medication and patient population. Working with a pharmacy partner that offers both options gives you the flexibility to choose the right format for each situation.

Regardless of which format you choose, look for these quality indicators from your pharmacy partner:

• Sterility testing on each lot before release
• Potency testing confirming labeled concentration
• Stability data supporting the assigned BUD
• Certificate of Analysis (CoA) available for each lot
• cGMP manufacturing (especially important for 503B-sourced preparations)
• Clear labeling including BUD, storage conditions, and reconstitution instructions (for lyophilized)

1. United States Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding — Sterile Preparations. 2023 Revision.
2. Wang W. Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics. 2000;203(1-2):1–60.
3. Manning MC, et al. Stability of protein pharmaceuticals: an update. Pharmaceutical Research. 2010;27(4):544–575.
4. U.S. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. FDA, 2004.
5. Carpenter JF, et al. Rational design of stable lyophilized protein formulations. Pharmaceutical Biotechnology. 2002;13:109–133.

MedClinic Partners connects licensed clinics and 503A pharmacies with vetted 503B supply and USA-made cGMP RUO peptides. Questions about formulation options? Use the Get Connected form to reach our team.